Antibodies for selective apoptosis of cells

A method of treating cancer or pathogen infection comprising administering to, or expressing in cells of a subject in need thereof a therapeutically effective amount of a recombinant isolated antibody capable of specifically binding an MHC-peptide complex, said recombinant isolated antibody being capable of inducing apoptosis of cancer cells or pathogen infected cells, said cancer cells or said pathogen infected cells specifically expressing said MHC-peptide complex, thereby treating the cancer or the pathogen infection in the subject.

Use of a recombinant isolated antibody capable of specifically binding an MHC-peptide complex, as a pharmaceutical, said recombinant isolated antibody being capable of inducing apoptosis of cancer cells or pathogen infected cells specifically expressing said MHC-peptide complex.

Use of a recombinant isolated antibody capable of specifically binding an MHC-peptide complex, said recombinant isolated antibody being capable of inducing apoptosis of cancer cells or pathogen infected cells specifically expressing said MHC-peptide complex, for the manufacture of a medicament identified for the treatment of cancer or pathogen infection.

A pharmaceutical composition for treating cancer or pathogen infection comprising as an active ingredient a recombinant isolated antibody capable of specifically binding an MHC-peptide complex in cancer cells or pathogen infected cells specifically expressing said MHC-peptide complex, said recombinant isolated antibody being capable of inducing apoptosis in said cancer cells or said pathogen infected cells and a pharmaceutically acceptable carrier.

A method of diagnosing cancer or pathogen infection in a subject, comprising:

• (a) contacting a biological sample of the subject with a recombinant isolated antibody capable of specifically binding an MHC-peptide complex under conditions suitable for immunocomplex formation;
• said recombinant isolated antibody being capable of inducing apoptosis in target cancer cells or pathogen infected cells, and
• (b) detecting formation of said immunocomplex, thereby diagnosing the cancer or pathogen infection in the subject.

A method of diagnosing cancer or pathogen infection in a subject, comprising:

• (a) contacting a biological sample of the subject with a recombinant isolated antibody capable of specifically binding an MHC-peptide complex under conditions suitable for immunocomplex formation, said recombinant isolated antibody being capable of inducing apoptosis in target cancer cells or pathogen infected cells;
• and
• (b) detecting a level of apoptosis in cells of said biological sample thereby diagnosing the cancer or pathogen infection in the subject.

A kit for diagnosing cancer or pathogen infection in a subject, the kit comprising packaging materials and at least one agent identified by said packaging materials as being suitable for an immunocomplex formation between a recombinant isolated antibody capable of specifically binding an MHC-peptide complex and said MHC-peptide complex, said recombinant isolated antibody being capable of inducing apoptosis in cancer cells or pathogen infected cells.

A recombinant antibody capable of inducing apoptosis in cancer cells or pathogen infected cells.

A pharmaceutical composition comprising a recombinant antibody capable of inducing apoptosis in cancer cells or pathogen infected cells, and a pharmaceutical acceptable carrier.

A recombinant 9H scFv as set forth by SEQ ID NO:1.

A recombinant CLA12 scFv as set forth by SEQ ID NO:17.

A recombinant antibody comprising at least one CDR selected from the group consisting of SEQ ID NOs:5-16 and 19-24.